# Gilead Sciences, Inc. – Consensus ‘buy’ rating and 9.4% Upside Potential

- Link: https://www.directorstalkinterviews.com/gilead-sciences-inc.consensus-buy-rating-and-9.4-upside-potential/4121131017
- Published: 2023-10-26T14:09:01+01:00
- Author: Charlotte Edwards

**Gilead Sciences, Inc.** which can be found using ticker (GILD) now have 24 confirmed
analysts covering the stock with the consensus suggesting a rating of ‘buy’. The
target price High/Low ranges between 109.4 and 66.96 and has a mean target at $85.47.
Given that the stocks previous close was at $78.15 this indicates there is a potential
upside of 9.4%. It’s also worth noting that there is a 50 day moving average of 
$76.40 and the 200 day moving average is $79.40. The market capitalization for the
company is 97.67B. The current share price for the company is: 78.39 USD

 The potential market cap would be $106,823,526,588 based on the market consensus.

The company is not paying dividends at this time.

Other points of data to note are a P/E ratio of 18.02, revenue per share of 21.87
and a 9.77% return on assets.

Gilead Sciences, Inc. is a biopharmaceutical company. The Company is engaged in 
advancing medicines to prevent and treat life-threatening diseases, including human
immunodeficiency virus (HIV), viral hepatitis and cancer. The Company offers products
in HIV, Onocolgy, Liver Disease, Vekulaery, and Other. Under HIV, it offers Biktarvy,
Complera/Eviplera, Genvoya, Odefsey, Stribild, and Truvada. Its Veklury (remdesivir)
is a nucleotide analog RNA polymerase inhibitor indicated for the treatment of coronavirus
disease 2019 (COVID-19). Under oncology it offers cell therapy containing Tecartus
and Yescarta. Under this Liver Disease consists of Chronic hepatitis C virus (HCV)(
Ledipasvir/Sofosbuvir and Sofosbuvir/Velpatasvir) and Chronic hepatitis B virus (
HBV) / hepatitis delta virus (HDV) (Vemlidy and Viread). The Company’s other products
include AmBisome and Letairis. It also operates a portfolio of small molecule inhibitors
targeting PARP1 for oncology and MK2 for inflammatory diseases.

Share on: